I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ASRS 2023

-
Coming soon
01:00 PM
Duration 8mins Virtual
Efficacy, durability, and safety of faricimab▼ in diabetic macular edema (DME): 1-year results from China subpopulation of phase 3 RHINE trial
Sun X, Lai T, Han M, Idowu O, Jiang Q, Lai C, Li X, Liu R, Liu W, Liu X, Tang Y, Wang Y, Willis J, Wu Z, Ye Z, Z L, Kotecha A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 8mins Virtual
Faricimab▼ Personalized Treat-and-Extend–based Dosing Dynamics in Patients With DME
Pearce I, Lim J, Chen SJ, Steinle N, Jaffe G, Gerendas B, Abreu F, Camino A, Gibson K, Jain N, Shildkrot E, Souverain A, Tang Y, Willis J, Haskova Z

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 8mins Virtual
Faricimab▼ Rapidly Improves Fluid Parameters in Patients With nAMD
London N, Querques G, Kotecha A, Willis J, Souverain A, Shildkrot E, Margaron P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 8mins Virtual
Faricimab▼ Reduces Macular Leakage vs Aflibercept in Patients With DME
Nudleman E, Goldberg R, Csaky K, Kolomeyer A, Gibson K, Mar F, Wang T, Willis J

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 8mins Virtual
Individualized Faricimab▼ Dosing up to Every 16 weeks Maintains Robust Anatomic and Vision Outcomes Through 2 years in nAMD
Chaudhary V, Kotecha A, Willis J, Souverain A, Shildkrot E, Swaminathan B, Margaron P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 8mins Virtual
Morph-interpolation visualizations of the effect of monthly intravitreal injections of faricimab▼ 6.0 mg in patients with DME from the BOULEVARD trial
Yonekawa Y, Glittenberg C, Maunz A, Haskova Z, Kotecha A, Gibson K, Singer M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 8mins Virtual
Real-world use of faricimab▼ to treat nAMD patients in the UK (FARWIDE Study)
Patel P, Talks J, DeSalvo G, Lotery A, Pearce I, De Silva S, Gale R, Varma D, McKibbin M, James N, Chi G, Downey A, Shah P, Dodds M, McGrory S, Dayal P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 8mins Virtual
Port Delivery System With Ranibizumab in Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema: Phase 3 Pavilion Trial Primary Analysis
Chang M, Emanuelli A, Holekamp N, Latkany P, Malhotra V, Brittain C, Howard D, Santhanakrishnan A, Wetzel-Smith M, Quezada-Ruiz C, Pieramici D

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 8mins Virtual
Regional Variance in the Enrollment of Underrepresented Patients in US Clinical Trials of DME
Khan, Amador, Blotner, Hill, Haller

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
08:49 AM
Duration 4mins Seattle Convention Center
An Assessment of the Impact of Disease Activity Criteria on Dosing Interval Assignment in Clinical Trial Patients With nAMD
Zarbin M, Weng, CY, Souverain A, Stoilov I, Margaron P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:54 PM
Duration 4mins Seattle Convention Center
A novel intravitreal anti-IL-6 monoclonal antibody for UME: preliminary results from the phase 1 DOVETAIL study
Sharma S, Suhler E, Lin P, Pauly-Evers M, Willen D, Peck R, Storti F, Rauhut S, Gott T, Passemard B, Macgregor L, Haskova Z, Silverman D, Fauser S, Mesquida M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
08:32 AM
Duration 4mins Seattle Convention Center
Long-term Efficacy and Safety of the Port Delivery System With Ranibizumab in Patients With nAMD: Results From the Portal 5-year Subgroup Analysis
Nielsen J, Howard J, Cavichini M, Singh N, Gune S

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
01:39 PM
Duration 4mins Seattle Convention Center
Elevatum Study Design and Rationale: Phase 4 Trial of Faricimab▼ (VABYSMO) in Underrepresented Patients with Diabetic Macular Edema
Coney J, Scott A, Amador M, Chang J, Stoilov I, Meldorf M, Gonzalez L, Cunningham M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
04:03 PM
Duration 6mins Seattle Convention Center
Impact of Faricimab▼ vs Aflibercept on Epiretinal Membrane Formation Over 2 Years in Eyes with DME in the YOSEMITE/RHINE Phase 3 Trials
Jaffe G, Ogura Y, Deak G, Gibson K, Schmidt-Erfurth U, Wang T, Westenskow P, Willis J

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
10:57 AM
Duration 4mins Seattle Convention Center
Faricimab▼ Causes Rapid and Sustained Intraocular Suppression of Ang-2 and VEGF-A for Up to 16 Weeks in nAMD and DME
Muni R, Bogman K, Diack C, Stoilov I

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
11:01 AM
Duration 4mins Seattle Convention Center
Time to Retinal Fluid Control With Faricimab▼ vs Aflibercept in Patients With DME in the Phase 3 YOSEMITE/RHINE Trials
Rachitskaya A, Gibson K, Mar F, Tang Y, Willis J

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
11:05 AM
Duration 4mins Seattle Convention Center
Early Treatment Patterns and Outcomes in Patients with Diabetic Macular Edema Treated with Faricimab▼: the FARETINA-DME Study
Borkar D, Tabano D, Garmo V, Leng T, Shaia J, Kuo B, Myers R, LaPrise A, Singh R

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
01:34 PM
Duration 4mins Seattle Convention Center
Early Treatment Patterns and Outcomes in Patients with Neovascular Age-Related Macular Degeneration Initiating Faricimab▼: the FARETINA-AMD Study
Leng T, Tabano D, Garmo V, Borkar D, Shaia J, Kuo B, Myers R, LaPrise A, Singh R

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
10:53 AM
Duration 6mins Seattle Convention Center
Port Delivery System With Ranibizumab (PDS) for Continuous Treatment in DME and DR: Additional Results From the Phase 3 Pagoda and Pavilion Trials
Marcus D, Graff J, Campochiaro P, Khanani A, Malhotra V, Latkany P, Gune S, Howard D, Santhanakrishnan A, Bobbala A, Chang M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar